article thumbnail

Some action points for the next PM

Express Pharma

The report goes on to advise that India’s pharma companies should invest more in developing capabilities to make generic copies of biologics (biogenerics), as more biologics are set to lose exclusivity in the period up to 2030. Biogenerics comes with higher risks, as the manufacturing process and technologies are more complex.

article thumbnail

Budget expectation: Bring GST rate on APIs at par with the formulations

Express Pharma

Due to the multiplicity of regulatory processes and multiple regulators, undertaking operations become complex and time consuming. million nurses/midwives in the total stock by 2030. This will also expand the scope for private health insurance companies to include them in their products, irrespective of the package cost.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHC Comments on Centers for Medicare & Medicaid Services (CMS) in response to the CY 2025 OPPS proposed rule

Putting Patients First Blog

16 We encourage CMS to continue refining these data collection processes to ensure they capture meaningful and actionable information. We believe this process is crucial for adapting the payment system to evolving clinical practices and emerging medical technologies.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Payers and manufacturers control the players in Specialty, so newcomers need significant support and guidance navigating the process.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Payers and manufacturers control the players in Specialty, so newcomers need significant support and guidance navigating the process.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Payers and manufacturers control the players in Specialty, so newcomers need significant support and guidance navigating the process.

article thumbnail

Disease of the Month: Age-Related Macular Degeneration (AMD)

PharmaShots

by 2030 Treatment: AMD treatment depends on the stage and type, currently no treatments options are available for early AMD. The interpretation showed that highest no.